{"id":"W4304609073","doi":"10.1093/ofid/ofac535","title":"Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhu GM-CSF) as Adjuvant Therapy for Invasive Fungal Diseases","year":2022,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Allergan; Shionogi; Sick Kids Foundation; Amplyx; Astellas Pharma; Ablynx; Karyopharm Therapeutics; Gilead Sciences; GlaxoSmithKline; Pfizer","keywords":"Medicine; Granulocyte macrophage colony-stimulating factor; Recombinant DNA; Adjuvant; Granulocyte colony-stimulating factor; Immunology; Colony-stimulating factor; Granulocyte; Internal medicine; Cytokine; Biology; Haematopoiesis; Chemotherapy; Stem cell; Cell biology; Biochemistry","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012934,0.0004808825,0.000840363,0.000234232,0.003125657,0.0003300492,0.000467001,0.00007725092,0.004575947],"category_scores_gemma":[0.0002507862,0.0004477764,0.0005698674,0.0004845789,0.0001441191,0.0004731692,0.0006027154,0.0003757947,0.00006603618],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000656883,"about_ca_system_score_gemma":0.0008207001,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00136426,"about_ca_topic_score_gemma":0.0004024482,"domain_scores_codex":[0.9971016,0.0002131896,0.0005610061,0.0008440234,0.000488653,0.0007915016],"domain_scores_gemma":[0.997812,0.0003607493,0.0003314176,0.0006731085,0.0002524699,0.0005702797],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002399075,0.003432116,0.9513669,0.0001610116,0.0005326772,0.0002383698,0.0002150245,0.0003924356,0.004010637,0.002345808,0.0241937,0.01071222],"study_design_scores_gemma":[0.03584757,0.02429404,0.8075348,0.000299115,0.001541751,0.0006075621,0.001436737,0.0001574681,0.004936504,0.012058,0.1092669,0.002019531],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9801862,0.001384165,0.00003946125,0.0008687057,0.001396502,0.006309946,0.001779637,0.0003688005,0.007666609],"genre_scores_gemma":[0.9869128,0.0001683879,0.00001735373,0.003142411,0.0002096516,0.005348927,0.0007170085,0.0001405153,0.003342978],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1438321,"threshold_uncertainty_score":0.9997974,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02595412161530459,"score_gpt":0.3355992346685612,"score_spread":0.3096451130532566,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}